Affiliations: Department of Pathology, Faculty of Medicine, Mansoura
University, Mansoura, Egypt | Department of Anatomic Pathology and Cytology,
GIGA-Cancer, University of Liege, Liege, Belgium
Note: [] Corresponding author: Philippe Delvenne, MD, PhD, Department of
Pathology B35, Chu Sart Tilman, 4000 Liege, Belgium. Tel.: +32 43662564; Fax:
+32 43662919; E-mail: p.delvenne@ulg.ac.be
Abstract: Cervical and endometrial uterine carcinomas are heterogeneous groups
of cancers, which are preceded by preneoplastic lesions. More accurate tools
are needed to improve the diagnosis and to define markers which may be relevant
for the diagnosis, prediction of disease progression and therapeutic response. High throughput technologies for testing and validating molecular targets in
cancer lesions and in their precursors are presently available. Among them, the
tissue microarray (TMA) presents the advantage of a morphological control of
the analyzed tissue fragment. In this article, we review the different aspects
of the TMA technology with a special consideration to a uterine carcinogenesis
model.
